Specify a stock or a cryptocurrency in the search bar to get a summary
Dermata Therapeutics Inc
DRMADermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California. Address: 3525 Del Mar Heights Road, San Diego, CA, United States, 92130
Analytics
WallStreet Target Price
6 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures DRMA
Dividend Analytics DRMA
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History DRMA
Stock Valuation DRMA
Financials DRMA
Results | 2019 | Dynamics |